Related Experiment Videos
Indomethacin therapy in premature infants of advanced postnatal age
Insights
Indomethacin treatment failed to close patent ductus arteriosus in older infants. This suggests some cases of persistent ductus arteriosus may be independent of prostaglandins.
Area of Science:
- Neonatal Medicine
- Pediatric Cardiology
- Pharmacology
Background:
- Patent ductus arteriosus (PDA) is a common condition in neonates.
- Indomethacin is a standard treatment for PDA closure.
- PDA persistence in older infants is less understood.
Purpose of the Study:
- To investigate the efficacy of indomethacin in older infants with persistent PDA.
- To explore potential prostaglandin independence in PDA closure.
Main Methods:
- Eight infants aged eight weeks or older with persistent PDA received intravenous indomethacin (0.3 mg/kg every 8 hours for 3 doses).
- Plasma indomethacin levels were monitored.
- Ductus closure was assessed.
Main Results:
- None of the eight infants achieved ductus closure despite therapeutic plasma indomethacin levels.
- This indicates a lack of response to indomethacin in this cohort.
Conclusions:
- A subset of infants with persistent PDA may be prostaglandin-independent.
- Alternative treatment strategies may be necessary for these cases.
Abstract:
Indomethacin (0.3 mg/kg every eight hours IV for three doses) was administered to eight infants whose postnatal ages were eight weeks or greater and who developed patent ductus arteriosus either in the late postnatal life or in the early neonatal period but persisted. In spite of maintenance of appropriate plasma indomethacin levels, none of the infants responded with ductus closure. The present study suggests that a distinct group of infants may exist whose ductus arteriosus is prostaglandin independent and the patency of the ductus may persist.